Summit shares drop after US FDA declines to approve lung cancer drug

By Reuters News

- Shares of Summit Therapeutics SMMT.O fell nearly 20% in premarket trading on Monday after the US Food and Drug Administration declined to approve its experimental lung cancer drug ivonescimab.

The regulator on Sunday cited the drug's failure to achieve statistical significance in overall survival, a key measure of long-term treatment benefit, in a late-stage study that formed part of Summit's marketing application.

The decision establishes a "meaningful regulatory precedent" for the drug class, with potential implications for similar drug candidates being developed by Bristol-Myers Squibb BMY.N, BioNTech 22UAy.DE, Pfizer PFE.N, Merck MRK.N and AbbVie ABBV.N, said BMO Capital analyst Evan Seigerman.

Ivonescimab is designed to block two proteins: PD-1, which helps cancer evade the immune system, and VEGF, which tumors use to grow blood vessels.

Summit's shares were down 19.9% at $11.33 before the bell.

https://www.reuters.com/graphics/SUMMIT-STOCK/SUMMIT-STOCK/zdpxbykebpx/chart.png

The company had sought approval for ivonescimab, in combination with chemotherapy, for previously treated patients with advanced non-squamous non-small cell lung cancer (NSCLC) carrying EGFR genetic mutations.

The condition is the most common type of lung cancer, with the EGFR mutation occuring in 10% to 15% of cases in the US, according to the American Lung Association.

The FDA's decision was consistent with the high bar the agency had previously set, TD Cowen analysts said after the move.

Analysts are now closely watching data from a separate late-stage study expected later this year, in which the drug in combination with chemotherapy was tested as a first-line treatment for patients with NSCLC.

The FDA's rejection on Sunday does not impact the probability of success for ivonescimab in first-line NSCLC, "which remains the substantially larger and more important commercial opportunity," TD Cowen analysts said.

Summit acquired rights to the drug in the US, Canada, Europe and Japan from China's Akeso 9926.HK in 2022 under a deal valued at up to $5 billion. Akeso retained rights in China and other markets.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.